Searched for
LENALIDOMIDE
Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announcedDr Reddy's Laboratories Q4 Results: Dr. Reddy's Laboratories reported a consolidated net profit at Rs 221 crore in the March-ended quarter ...12 May, 2026, 05.08 PM IST- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...08 May, 2026, 10.19 PM IST
- Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommendedBiocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...08 May, 2026, 04.28 PM IST
- Biocon Q4 Results: Net profit down 57% at Rs 198.6 croreBiocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...08 May, 2026, 10.05 AM IST
- Sun Pharma most exposed Indian company to Trump's new tariff threat, warns JefferiesIndian drug maker Sun Pharma faces significant exposure to potential US tariffs on medicines. Global brokerage Jefferies warns that while g...02 Apr, 2026, 03.23 PM IST
- Our key business segments well positioned for growth: CS Muralidharan, Sun PharmaHowever, our outlook on speciality products remains very positive and I expect our existing products will continue to grow. Even in the cur...02 Aug, 2024, 02.59 PM IST
- Natco Pharma launches additional strengths of generic version of Revlimid in USNatco Pharma Ltd on Friday said it has launched additional strengths for its generic lenalidomide capsules used in the treatment of multipl...10 Mar, 2023, 01.26 PM IST
- Sun Pharma gets USFDA nod to market generic medicationIn June 2021, Sun Pharma entered into a settlement with Celgene Corporation (Celgene) to resolve the patent litigation regarding its generi...10 Feb, 2023, 01.15 PM IST
- Dr Reddy's launches generic Revlimid in US market"We are pleased with the first-to-market launch of two of our six strengths of Lenalidomide Capsules with 180-day market exclusivity. Bring...08 Sep, 2022, 01.04 PM IST
- Dr Reddy's gets FDA nod for generic Revlimid; enjoys 180 days exclusivity"We are pleased with the Agency's approval of Lenalidomide Capsules, 2.5 mg and 20 mg and being eligible for 180-day market exclusivity. We...19 Oct, 2021, 12.22 PM IST
- Dr Reddy's launches cancer drug in Canada"Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada's Multiple Myeloma ...02 Sep, 2021, 09.59 AM IST
- Sun Pharma settles patent litigation with Celgene Corporation for cancer drug RevlimidDrug major Sun Pharma has reached an agreement with Celgene Corporation, to resolve the patent litigation regarding generic version of Revl...22 Jun, 2021, 11.18 AM IST
- Sun Pharma inches up as the company settles a patent litigationPursuant to the terms of the settlement, Celgene will grant Sun Pharma a licensc to Celgene’s patents required to manufacture and sell (sub...22 Jun, 2021, 10.27 AM IST
- Natco Pharma's Canadian unit signs pact with Celgene for cancer treatment drugNatco Pharma entered into an agreement with biopharmaceutical firm Celgene for Lenalidomide capsules, which is used to treat various types ...10 Jul, 2020, 12.48 PM IST
- Dr Reddy's settles case with Celgene on cancer drugREVLIMID (Lenalidomide) is indicated for treatment for multiple myeloma (cancer).02 Apr, 2019, 03.45 PM IST
- Natco settles patent litigation with Celgene on cancer drugNatco and its US partner Allergan have settled a pending litigation with Celgene regarding generic Lenalidomide capsules used for treatment...23 Dec, 2015, 02.23 PM IST
- Natco Pharma introduces Lenalidomide genericNatco Pharma has introduced the generic version of Lenalidomide, which is indicated for the treatment of Myelo Dysplastic Syndrome.11 Sep, 2007, 02.40 PM IST
Load More
